文献速递其他结缔组织病

中性粒细胞与淋巴细胞比值作为系统性硬化症自体造血干细胞移植后临床缓解的生物标志物

Neutrophil-to-lymphocyte ratio as a biomarker for clinical response after autologous haematopoietic stem cell transplantation in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该回顾性研究纳入进展性弥漫型系统性硬化症患者,比较自体造血干细胞移植组、利妥昔单抗联合吗替麦考酚酯组和嵌合抗原受体T细胞治疗组与健康对照的中性粒细胞与淋巴细胞比值变化。仅自体造血干细胞移植组中性粒细胞与淋巴细胞比值在24个月内显著下降,且与改良Rodnan皮肤评分和用力肺活量%预计值相关。作者认为移植后中性粒细胞与淋巴细胞比值下降可能提示缓解,升高可能与病情加重相关,需进一步研究验证。

要点

  • 自体造血干细胞移植组、联合治疗组和CAR-T组基线平均NLR均高于健康对照(>2.95)。
  • 仅自体造血干细胞移植组NLR在24个月内显著下降,且与mRSS和FVC%相关。
  • 自体造血干细胞移植后复发的2例患者NLR升高至3以上。

核心结论

  • NLR是简单生物标志物,在自体造血干细胞移植后与系统性硬化症结局指标相关,但与常规治疗或CAR-T治疗不相关。
  • 作者建议自体造血干细胞移植后NLR下降可能提示缓解,而升高可能与病情加重相关。
  • 作者指出需进一步研究验证这些新发现。

研究设计与样本

  • 回顾性研究,纳入进展性弥漫型系统性硬化症患者,分为自体造血干细胞移植组(15例)、利妥昔单抗联合吗替麦考酚酯组(15例)和嵌合抗原受体T细胞治疗组(6例),并设健康对照组。
  • 在2年内重复评估NLR、改良Rodnan皮肤评分和用力肺活量%预计值。

主要发现

  • 自体造血干细胞移植组、联合治疗组和CAR-T组基线平均NLR均高于健康对照(>2.95)。
  • 所有治疗组在至12个月的各时间点mRSS值均显著下降、FVC%均显著升高。
  • 线性混合模型显示,仅自体造血干细胞移植组NLR在至24个月显著下降。
  • NLR与mRSS和FVC仅在自体造血干细胞移植组相关。
  • 自体造血干细胞移植后复发的2例患者NLR升高至3以上。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究验证这些新发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: SSc is a complex disease that affects various target organs, making it difficult to assess response and determine remission or relapse. A baseline neutrophil-to-lymphocyte ratio (NLR) >2.95 is associated with severe progressive skin and lung disease and decreased 5-year survival in SSc. However, it is unknown whether NLR changes in response to treatment. To retrospectively evaluate NLR changes as a biomarker for treatment response in SSc. METHODS: Progressive diffuse SSc patients who were treated with autologous haematopoietic stem cell transplantation (AHSCT group), with combination therapy of rituximab and MMF (combination group) or chimeric antigen receptor-T-cell (CAR-T) therapy group, were recruited along with healthy controls (HC group). NLR, modified Rodnan Skin Score (mRSS) and forced vital capacity (FVC)% predicted were repeatedly assessed over 2 years. RESULTS: Fifteen patients were recruited in the AHSCT group, 15 in the combination group and 6 patients in the CAR-T group. Baseline mean NLR was high (>2.95) in AHSCT, combination groups and CAR-T compared with HC. All treatment arms showed a statistically significant decrease in mRSS values and an increase in FVC% at each time point up to 12 months. In a linear mixed model, NLR significantly decreased up to 24 months only in the AHSCT group. NLR correlated with mRSS and FVC exclusively in the AHSCT group. NLR increased above 3 in two patients who experienced a relapse after AHSCT. CONCLUSION: NLR is a simple biomarker that correlated with outcome measures in SSc following AHSCT but not with conventional therapy or CAR-T therapy. It is suggested that a decrease in NLR following AHSCT may indicate remission, whereas an increase may be associated with exacerbation. Further research is needed to validate these novel findings.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Keret S, Kaly L, Schett G, et al. Neutrophil-to-lymphocyte ratio as a biomarker for clinical response after autologous haematopoietic stem cell transplantation in systemic sclerosis. Rheumatology (Oxford). 2025. PMID: 39485492. doi:10.1093/rheumatology/keae606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。